|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2005-6-6
|
|
pubmed:abstractText |
Capecitabine is a three-step prodrug that was rationally designed to be a more effective and safer alternative to its intermediate metabolite, 5'-deoxy-5-fluorouridine (5'-DFUR). We compared the pharmacokinetics/pharmacodynamics of these drugs in metastatic breast cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
205-11
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15844007-Administration, Oral,
pubmed-meshheading:15844007-Adult,
pubmed-meshheading:15844007-Aged,
pubmed-meshheading:15844007-Antimetabolites, Antineoplastic,
pubmed-meshheading:15844007-Area Under Curve,
pubmed-meshheading:15844007-Breast Neoplasms,
pubmed-meshheading:15844007-Deoxycytidine,
pubmed-meshheading:15844007-Female,
pubmed-meshheading:15844007-Floxuridine,
pubmed-meshheading:15844007-Fluorouracil,
pubmed-meshheading:15844007-Humans,
pubmed-meshheading:15844007-Middle Aged
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
|
|
pubmed:affiliation |
Division of Oncology/Hematology, Department of Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Clinical Trial, Phase II
|
